Although no evidence surfaced that Kodak broke the law, the investigation’s findings did determine that Kodak was at fault for disclosing the details of the loan to its executives a day prior to the official announcement. The loan was made to allow Kodak to launch a pharmaceuticals division to produce generic drug ingredients in response to the COVID-19 pandemic.
During the official announcement in July, President Trump hailed the plan as “a breakthrough in bringing pharmaceutical manufacturing back to the United States.” Currently, the deal is at a standstill while the Securities and Exchange Commission probes how the federal loan took place, as well as the unusual and sudden resulting stock surge of over 2,000% that took place in late July.
Kodak made it known on Tuesday that it planned to review and implement the special committee’s recommendations. “Kodak is committed to the highest levels of governance and transparency, and it is clear from the review’s findings that we need to take action to strengthen our practices, policies and procedures,” Kodak CEO Jim Continenza said Tuesday in a statement.
More from GOBankingRates
- 44 Ways To Trim Your Living Expenses During the Coronavirus Quarantine
- 94 Money-Making Skills You Can Learn in Less Than a Year
- 24 Ways To Maximize Your Paycheck This Year
- How Long $1 Million in Savings Will Last in Every State